Pharmafile Logo

Yervoy

Bayer symbol

Bayer nets speedy US review for regorafenib in liver cancer

Priority review in HCC boosts hopes for rejuvenation of Stivarga to combat declining sales

- PMLiVE

Keytruda closes in on Opdivo’s lead in Hodgkin lymphoma

KEYNOTE-087 trial shows an overall response rate of 69 percent

- PMLiVE

Keytruda gets priority FDA review for biomarker-positive tumours

Merck & Co’s immuno-oncology drug used for colorectal cancer

Bristol-Myers Squibb (BMS) building

Opdivo gets green light for Hodgkin lymphoma in Europe

Becomes the first PD-1 inhibitor to receive EU licence in this indication

- PMLiVE

Ono faces steep price cut for Opdivo in Japan

Japanese regulator proposes 50% cut after drug’s population growth exceeds initial projections

Bristol-Myers Squibb (BMS) building

BMS teams up with Infinity Pharmaceuticals for Opdivo study

Will test dual therapy potential in targeting tumour resistance to checkpoint inhibitors

- PMLiVE

SMC approves Opdivo combo as first-line skin cancer treatment

Also backs Gilead’s Epclusa, Baxalta’s Oncaspar, AZ’s Lynparza and Amicus’ Galafold

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

EMA starts review of Pfizer and Merck’s PD-L1 inhibitor

Avelumab looks set to be the first new drug to treat Merkel cell carcinoma

Bristol-Myers Squibb (BMS) building

Opdivo drives gain in BMS sales, but business revamp coming

Plans to invest in biologics production with potential divestment of older brands

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links